Denosumab in early-stage breast cancer

Lancet Oncol. 2019 May;20(5):e234-e235. doi: 10.1016/S1470-2045(19)30146-9.

Authors

Mariana Brandão¹, Márcio Debiasi², Evandro de Azambuja³

Affiliations

¹ Institut Jules Bordet - Université Libre de Bruxelles, 1000 Brussels, Belgium.
² Breast International Group, Brussels, Belgium.
³ Institut Jules Bordet - Université Libre de Bruxelles, 1000 Brussels, Belgium. Electronic address: evandro.azambuja@bordet.be.

PMID: 31044711
DOI: 10.1016/S1470-2045(19)30146-9

No abstract available

Publication types

Letter
Comment

MeSH terms

Bone Density Conservation Agents*
Breast Neoplasms*
Denosumab
Disease-Free Survival
Double-Blind Method
Humans
Postmenopause

Substances

Bone Density Conservation Agents
Denosumab